CION Ameerpet
Risk Factors Explained · Reviewed by CION Oncologists · NABH Accredited
How Excess Oestrogen Drives Endometrial Cancer
Most lists of risk factors for this disease read as a jumble — obesity, diabetes, PCOS, hormone therapy, never having children, late menopause. They are not a jumble. They are all the same thing described from different angles: oestrogen acting on the lining of the womb without enough progesterone to balance it. Understand that one mechanism and the whole list becomes obvious, including why some things protect you. It also explains why this is one of the more preventable cancers, and what a doctor is actually trying to do when they recommend a hormone device or a regular withdrawal bleed.
- Oestrogen tells the lining to grow — progesterone is what tells it to stop
- Unopposed means growth with no brake — the lining keeps building, month after month
- Every major risk factor fits this — weight, anovulation, hormone therapy, reproductive history
- It does not explain every case — the Type 2 cancers arise by a different route entirely
17+
Cancer Specialists
on Panel
on Panel
35+
Centres
Across India
Across India
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
The Mechanism, in Four Sentences
The endometrium is unusual among tissues in that it is designed to be built up and torn down every month. Two hormones run that cycle, and they do opposite jobs.
- Oestrogen is the growth signal. In the first half of a normal cycle it tells the lining to thicken and its glands to multiply, preparing for a possible pregnancy.
- Progesterone is the brake. It is produced by the ovary only after an egg is released. It stops the proliferation, matures the tissue, and — if there is no pregnancy — brings about an organised shed.
- No ovulation means no brake. Oestrogen keeps arriving and nothing stops it. The lining goes on proliferating rather than maturing and clearing.
- Sustained proliferation accumulates errors. Every cell division is an opportunity for a copying mistake. A tissue kept dividing for years, without the regular reset that shedding provides, accumulates changes — first hyperplasia, and in some women eventually cancer.
That intermediate step is important and it is where most of the opportunity lies. Endometrial hyperplasia is a visible, diagnosable, treatable state that sits between a normal lining and a cancer — which is why this disease has a genuine prevention story rather than only an early-detection one.
Did You Know? The single most under-appreciated fact about this disease is that the ovaries are not the only source of oestrogen — and after the menopause they are not the main one. Fat tissue contains an enzyme that converts circulating androgens into oestrogen, so adipose tissue is itself an oestrogen-producing organ. In a postmenopausal woman whose ovaries have shut down, body fat becomes the dominant source, and there is no ovulation and therefore no progesterone to oppose it. That is the whole explanation for why obesity is by a wide margin the largest modifiable risk factor for endometrial cancer, and why it continues to matter after the menopause rather than less. Sources: World Cancer Research Fund / American Institute for Cancer Research continuous update on endometrial cancer; The Cancer Genome Atlas integrated genomic characterisation of endometrial carcinoma; NCCN Clinical Practice Guidelines in Oncology — Uterine Neoplasms.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Where the Unopposed Oestrogen Comes From
Every established risk factor for this cancer is on this table, and each is either a source of extra oestrogen or a reason the progesterone brake is missing.
| Factor | What it does | More detail |
|---|---|---|
| Excess body weight | Adds oestrogen. Fat tissue converts androgens into oestrogen, and after the menopause becomes the main source. | Obesity and endometrial cancer |
| Cycles without ovulation | Removes the brake. No egg released means no progesterone, so oestrogen acts unopposed. | PCOS and endometrial cancer |
| Oestrogen without a progestogen | Adds oestrogen and removes the brake simultaneously — the most direct version of the mechanism. | Oestrogen-only HRT |
| Diabetes and insulin resistance | Amplifies the effect, and contributes independently through growth-signalling pathways. | Diabetes and endometrial risk |
| Early first period, late menopause | Increases the total number of cycles, and therefore lifetime exposure. | Late menopause and risk |
| Never having been pregnant | Pregnancy is nine months of very high progesterone. Never having one removes that protection. | Nulliparity and risk |
| Some hormonal breast cancer treatments | Act as an oestrogen-like signal on the uterine lining while blocking oestrogen in the breast. | The breast cancer link |
| Combined hormonal contraception | Protective — it supplies a progestogen continuously, and the protection persists for years after stopping. | Do birth control pills lower risk? |
Notice what the last row does. The same mechanism that explains the risks also explains the protections, and that is the strongest evidence that the mechanism is real. Anything that supplies progesterone, or reduces oestrogen, or interrupts continuous proliferation lowers risk — pregnancy, breastfeeding, combined contraception, a hormone-releasing device, weight reduction.
Want Your Own Exposure Assessed?
Weight, cycles, hormone use and family history together give a much better picture than any one of them alone.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
One Mechanism, and Several Places to Interrupt It
This is among the more preventable cancers, precisely because the pathway is so well understood.
Where This Explanation Stops
It would be misleading to present unopposed oestrogen as the whole story, because a meaningful minority of endometrial cancers do not arise this way at all.
Endometrial cancers are broadly divided into two groups. The oestrogen-driven ones — historically called Type 1 — are the majority: endometrioid in type, usually low grade, preceded by hyperplasia, hormone-receptor positive, and typically found early. Everything on this page describes them.
The Type 2 cancers are different in almost every respect:
- They are not driven by oestrogen exposure. They often arise on a thin, atrophic lining in an older woman, without the hyperplasia that precedes the oestrogen-driven type.
- They include serous and clear cell carcinoma and carcinosarcoma. These behave more aggressively, are regarded as high grade by definition, and are managed more intensively even when found early. See Type 2 endometrial cancer.
- The risk factors do not map the same way. Weight and anovulation are less central. This is why a slim woman with regular cycles is not immune, and why any postmenopausal bleeding is investigated regardless of risk profile.
- Molecular classification has largely superseded the two-group model. Endometrial cancers are now sorted into four molecular groups, which predict behaviour better than the Type 1 / Type 2 split. See MMR and MSI testing and grades explained.
And separately from all of this, a minority of cases are inherited through Lynch syndrome, where the driver is a fault in DNA repair rather than hormone exposure.
Several Risk Factors and Not Sure What to Do About Them?
The useful conversation is about which ones are modifiable in your case and what order to tackle them in. The opinion is free.
Where the Mechanism Can Be Interrupted
Because the pathway is understood, there are several practical points at which it can be broken. These are the ones that actually work.
Largest effect
Reducing Body Weight
Directly reduces the oestrogen produced outside the ovaries, and improves insulin resistance at the same time. The single most effective modifiable step. See obesity and risk.
Direct
Restoring a Regular Bleed
In women with infrequent cycles, ensuring a withdrawal bleed at regular intervals supplies the missing progesterone effect. This is why it is standard advice in PCOS.
Direct
A Hormone-Releasing Device
Delivers progestogen straight to the lining at high local concentration. Used both to prevent hyperplasia and to treat it. See the hormone IUD.
Direct
Adding a Progestogen to HRT
In any woman with a uterus, oestrogen replacement must include a progestogen. This is not optional and it exists solely to protect the endometrium.
Supporting
Treating Diabetes and Insulin Resistance
Addresses a driver that operates alongside the oestrogen pathway, and is highly relevant across Telangana and Andhra Pradesh. See diabetes and risk.
Detection
Acting on Abnormal Bleeding
The mechanism produces bleeding long before it produces anything dangerous. Reporting it is what turns a preventable pathway into a prevented one. See postmenopausal bleeding.
Why Understanding the Mechanism Changes the Conversation
A list of risk factors is frightening. A mechanism with several points of interruption is actionable.
45-minute consultations
Scan and biopsy in one visit
Lynch counselling built in
Survivorship care that is actually offered
Second opinions welcomed, not resented
Decisions for healing, not billing
Take The Next Step
This Is One of the More Preventable Cancers
Because the pathway is known, and because it announces itself long before it becomes dangerous.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Oestrogen & Endometrial Cancer — Frequently Asked Questions
How does oestrogen cause endometrial cancer?
Oestrogen is the growth signal for the lining of the womb — it tells the tissue to thicken and its glands to multiply. Progesterone is the brake, and it is produced by the ovary only after an egg is released. In a normal cycle, growth is followed by a brake and then an organised shed. Where progesterone is absent or insufficient, oestrogen keeps stimulating the lining and nothing stops it, so the tissue proliferates continuously instead of maturing and clearing. Sustained proliferation over years accumulates cellular changes, producing first endometrial hyperplasia and, in some women, eventually carcinoma. This is why the condition is described as driven by "unopposed" oestrogen rather than by oestrogen as such.
Where does the excess oestrogen come from if my ovaries have stopped working?
From fat tissue, which is itself an oestrogen-producing organ. It contains an enzyme that converts circulating androgens into oestrogen, and after the menopause — when ovarian production has ceased — adipose tissue becomes the dominant source. Crucially, there is no ovulation after the menopause and therefore no progesterone at all to oppose it. This is the explanation for why obesity is by a wide margin the largest modifiable risk factor for endometrial cancer, and why its importance increases rather than decreases after the menopause. It is also why weight matters even in a woman whose ovaries have been surgically removed.
Does this mean all endometrial cancer is caused by hormones?
No, and it is important not to overstate the mechanism. The oestrogen-driven cancers — historically called Type 1 — are the majority: endometrioid in type, usually low grade, preceded by hyperplasia, hormone-receptor positive and typically found early. But a meaningful minority arise by a different route. The Type 2 cancers, which include serous carcinoma, clear cell carcinoma and carcinosarcoma, often develop on a thin atrophic lining in an older woman without any preceding hyperplasia, are not driven by oestrogen exposure, and behave more aggressively. Separately, a minority of cases are inherited through Lynch syndrome, where the driver is faulty DNA repair rather than hormones.
If oestrogen is the problem, is HRT dangerous?
Combined HRT — oestrogen with a progestogen — is not the problem this page describes, because the progestogen supplies exactly the opposition that is otherwise missing. The dangerous arrangement is oestrogen given alone to a woman who still has her uterus, which is the most direct form of unopposed exposure and is why oestrogen-only preparations are appropriate only after a hysterectomy. If you have a uterus and are taking oestrogen without a progestogen, that is worth clarifying with your prescriber. The progestogen component can be a tablet, part of a combined patch, or a hormone-releasing intrauterine device, and it exists specifically to protect the endometrium.
What actually lowers the risk?
Anything that reduces oestrogen exposure, supplies progesterone, or interrupts continuous proliferation. Weight reduction has the largest effect because it directly reduces the oestrogen produced outside the ovaries and improves insulin resistance at the same time. In women with infrequent cycles, ensuring a regular withdrawal bleed — through combined hormonal contraception, cyclical progestogen or a hormone-releasing intrauterine device — supplies the missing progesterone effect. Combined hormonal contraception is protective and the protection persists for years after stopping. Pregnancy and breastfeeding are protective for the same reason. And treating diabetes and insulin resistance addresses a driver operating alongside the hormonal pathway.
Medical disclaimer: This page explains the biological mechanism underlying most endometrial cancer and is reviewed by a CION oncologist, following current NCCN guidance and World Cancer Research Fund evidence reviews. It describes risk at a population level and does not predict what will happen to any individual; many women with several risk factors never develop this cancer, and some women with none do. It is general health information rather than advice about your own case. Do not stop or change prescribed hormone treatment on the basis of this page.